Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy

Leukemia volume 19, pages 1092–1094 (2005)Cite this article

TO THE EDITOR

There has been a controversy about the prognostic impact of myeloid antigens (MyAgs) in ALL. The issue has now regained significance since an anti-CD33 monoclonal antibody (mAb) is available for clinical treatment, which is considered for AML as well as for CD33pos ALL.1, 2, 3 We evaluated the prognostic impact of MyAgs in uniformly treated patients. From 9/1996 to 10/2002, 343 children with ALL were enrolled in a Czech nationwide study ALL-BFM95. In 327 patients (96%) immunophenotyping and molecular genetics were performed centrally in our reference labs. Prednisone good responders (PGR) with WBC at diagnosis <20000/μL and age 1–5 years were assigned into standard risk group (SRG). High RG (HRG) corresponded to prednisone poor response (PPR) or no remission at day 33 or BCR/ABL or MLL/AF4 fusions. The remaining patients were in the intermediate RG (IRG). Full statistics details are in the Supplementary Information.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17: 468–470.

    Article  CAS  Google Scholar 

  2. Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 2003; 17: 2247–2248.

    Article  CAS  Google Scholar 

  3. Cotter M, Rooney S, O'Marcaigh A, Smith OP . Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 687–688.

    Article  Google Scholar 

  4. Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90: 28–35.

    CAS  PubMed  Google Scholar 

  5. Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92: 795–801.

    CAS  Google Scholar 

  6. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931–3939.

    CAS  Google Scholar 

  7. Wiersma SR, Ortega J, Sobel E, Weinberg KI . Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800–808.

    Article  CAS  Google Scholar 

  8. Fink FM, Koller U, Mayer H, Haas OA, Grumayer-Panzer ER, Urban C et al. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group. Med Pediatr Oncol 1993; 21: 340–346.

    Article  CAS  Google Scholar 

  9. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987; 316: 1111–1117.

    Article  CAS  Google Scholar 

  10. Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198–202.

    CAS  PubMed  Google Scholar 

  11. Den Boer ML, Kapaun P, Pieters R, Kazemier KM, Janka-Schaub GE, Veerman AJ . Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance. Br J Haematol 1999; 105: 876–882.

    Article  CAS  Google Scholar 

  12. Firat H, Favier R, Adam M, Leverger G, Landman-Parker J, Cayre Y et al. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. Leuk Lymphoma 2001; 42: 675–682.

    Article  CAS  Google Scholar 

  13. van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hahlen K et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523–1533.

    CAS  Google Scholar 

  14. Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005 (in press).

  15. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18: 983–988.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank J Ridoskova, K Pospisilova, L Gondorcinova, P Hanusova and N Holosova for technical assistance. Collaboration of Czech Pediatric Hematology (CPH) centers (data manager A Vrzalova, leaders: B Blazek (Ostrava), Z Cerna (Plzen), Y Jabali (Ceske Budejovice), V Mihal (Olomouc), D Prochazkova (Usti nad Labem), J Sterba (Brno), J Hak and K Tousovska (Hradec Kralove)) and statistical help of P. Martinkova is appreciated. The work was supported by grants: GA UK 80 and 65 (2004), MZ CR 7430-3 and MSM0021620813.

Author information

Authors and Affiliations

  1. CLIP (Childhood Leukemia Investigation Prague), 2nd Medical School, Charles University, Prague, Czech Republic

    E Mejstříková, T Kalina, J Trka & O Hrušák

  2. Department of Immunology, 2nd Medical School, Charles University, Prague, Czech Republic

    E Mejstříková, T Kalina & O Hrušák

  3. Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, Prague, Czech Republic

    J Trka & J Starý

Authors
  1. E Mejstříková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Kalina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Trka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Starý
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Hrušák
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Hrušák.

Additional information

Supplementary Information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mejstříková, E., Kalina, T., Trka, J. et al. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia 19, 1092–1094 (2005). https://doi.org/10.1038/sj.leu.2403737

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403737

This article is cited by

Search

Advanced search

Quick links